A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
Patients with diabetic DED can experience inflammatory biomarker reductions and sign and symptom improvements with topical insulin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback